Genprex, Inc. (GNPX)
NASDAQ: GNPX · Real-Time Price · USD
1.960
-0.040 (-2.00%)
At close: Mar 12, 2026, 4:00 PM EDT
1.950
-0.010 (-0.51%)
After-hours: Mar 12, 2026, 7:58 PM EDT
Genprex Employees
Genprex had 13 employees as of September 30, 2025. The number of employees decreased by 6 or -31.58% compared to the same quarter last year.
Employees
13
Change
-6
Growth
-31.58%
Revenue / Employee
n/a
Profits / Employee
-$1,289,939
Market Cap
4.55M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 13 | -6 | -31.58% | 13 | 0 |
| Jun 30, 2025 | 15 | -6 | -28.57% | 15 | 0 |
| Mar 31, 2025 | 15 | -11 | -42.31% | 15 | 0 |
| Dec 31, 2024 | 16 | -10 | -38.46% | 16 | 0 |
| Sep 30, 2024 | 19 | -12 | -38.71% | 19 | 0 |
| Jun 30, 2024 | 21 | -9 | -30.00% | 21 | 0 |
| Dec 31, 2023 | 26 | -2 | -7.14% | 26 | 0 |
| Sep 30, 2023 | 31 | 9 | 40.91% | 31 | 0 |
| Jun 30, 2023 | 30 | 8 | 36.36% | 30 | 0 |
| Mar 31, 2023 | 28 | 9 | 47.37% | 28 | 0 |
| Dec 31, 2022 | 28 | 11 | 64.71% | 28 | 0 |
| Sep 30, 2022 | 22 | 6 | 37.50% | 22 | 0 |
| Jun 30, 2022 | 22 | 6 | 37.50% | 22 | 0 |
| Mar 31, 2022 | 19 | 7 | 58.33% | 19 | 0 |
| Dec 31, 2021 | 17 | 5 | 41.67% | 17 | 0 |
| Sep 30, 2021 | 16 | 4 | 33.33% | 16 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aptevo Therapeutics | 37 |
| Lunai Bioworks | 29 |
| GeoVax Labs | 17 |
| VivoSim Labs | 14 |
| Revelation Biosciences | 9 |
| MetaVia | 9 |
| Indaptus Therapeutics | 7 |
| Oragenics | 5 |
GNPX News
- 2 days ago - Genprex to Participate at BIO Europe Spring 2026 - PRNewsWire
- 17 days ago - Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer - PRNewsWire
- 4 weeks ago - Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers - PRNewsWire
- 2 months ago - Genprex Provides Clinical Update on Diabetes Gene Therapy Program - PRNewsWire
- 2 months ago - Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies - PRNewsWire
- 3 months ago - Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer - PRNewsWire
- 4 months ago - Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials - PRNewsWire
- 4 months ago - Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers - PRNewsWire